OX40 — Drug Target

All drugs that target OX40 — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

OX40 agonist monoclonal antibody

Phase 3 pipeline (4)

• MK-3415A · Merck Sharp & Dohme LLC · OX40 agonist monoclonal antibody · Oncology
  MK-3415A is a monoclonal antibody that targets and inhibits OX40, a costimulatory immune checkpoint receptor, to enhance T-cell activation and anti-tumor immunity.
• KW-2246 · Kyowa Kirin Co., Ltd. · OX40 agonist monoclonal antibody · Oncology
  KW-2246 is a humanized monoclonal antibody that binds to and inhibits OX40, a co-stimulatory immune checkpoint receptor, to enhance T-cell activation and anti-tumor immunity.
• KN057 · Suzhou Alphamab Co., Ltd. · OX40 agonist monoclonal antibody · Oncology
  KN057 is a monoclonal antibody that targets and blocks the OX40 receptor to enhance anti-tumor immune responses.
• PF-05280586 · Pfizer · OX40 agonist monoclonal antibody · Oncology
  PF-05280586 is a monoclonal antibody that blocks OX40, a costimulatory receptor on T cells, to enhance anti-tumor immune responses.